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Introduction: Somatic LKB1 mutations are found in lung adeno-
carcinomas at different frequencies in Caucasian and East Asian
(Japanese and Korean) populations. This study was designed to
characterize the frequency of LKB1 mutations, their relationship to
EGFR and KRAS mutations, and their associated clinicopathologic
characteristics in Chinese patients.
Methods: Two hundred thirty-nine lung adenocarcinomas consec-
utively collected from October 2007 to July 2009 were dissected
into 3 to 4 small (3 mm) pieces for histopathological analyses of
tumor content. Genomic DNA and/or cDNA from 86 samples with
more than 70% tumor content were used for sequencing of LKB1
(exons 1–9), EGFR (exons 18–21), and KRAS (exon 2). LKB1
germline mutation status was determined by sequencing of genomic
DNA from matched histologically distant lung tissues that are
histologically normal.
Results: 6.9% of lung adenocarcinomas harbored LKB1 somatic
mutations. A total of 10.5% of patients had an LKB1 germline
polymorphism, F354L. Interestingly, in two of these patients, tu-
mors displayed loss of heterozygosity at this allele. EGFR kinase
domain and KRAS mutations were found in 66.3% and 2.3% of
Chinese lung adenocarcinomas, respectively. Concurrent LKB1 and
EGFR somatic mutations were observed in one patient. Both KRAS-
mutant tumors harbored LKB1 mutations.
Conclusions: These data provide important clinical and molecular
characteristics of lung adenocarcinomas from Chinese patients.
Key Words: Chinese lung adenocarcinoma, LKB1, EGFR, KRAS,
Mutation.
(J Thorac Oncol. 2010;5: 1130–1135)
Lung cancer is the leading cause of cancer-related death inChina.1 An estimated 400,000 patients die of lung cancer
in China annually.2 Lung adenocarcinoma is the most com-
mon histologic subtype, accounting for approximately 40%
of lung cancer cases worldwide.3,4 The 5-year overall survival
of patients with lung cancer is about 15%, highlighting the
need for novel treatment strategies.
Previous studies in lung adenocarcinomas have identi-
fied several oncogenic mutations in genes encoding signaling
molecules including LKB1, EGFR, and KRAS.5–8 The muta-
tional status of these genes in tumors has implications for
targeted therapy.8–13 Thus, an understanding of the spectrum
of these mutations in different ethnic populations is important
for the development of therapeutic strategies in different
countries.
LKB1 encodes for a serine-threonine kinase. LKB1
gene mutation is the causal genetic factor of the rare inher-
itable disease Peutz-Jeghers syndrome.14,15 Patients with
Peutz-Jeghers syndrome are susceptible to many types of
cancers in different organs, among which gastrointestinal
tract cancers are most frequently observed.16,17 Interestingly,
somatic mutations of LKB1 have been consistently observed
in human non-small cell lung cancer, with the highest muta-
tion rate found in lung adenocarcinomas from Caucasian
patients (30%).18,19 Lower rates are found in Korean
(8%) and Japanese (7%) populations,20,21 underscoring a
significant difference of LKB1 mutations in patients of dif-
ferent ethnicities.
Similarly, the frequency of mutations in EGFR and
KRAS seems to be different in Asian and Caucasian lung
cancer patients. EGFR encodes for the epidermal growth
factor receptor. EGFR mutations, which are more commonly
found in “never smokers” (100 cigarettes in life time), are
associated with increased sensitivity to the EGFR tyrosine
kinase inhibitors, gefitinib, and erlotinib.22,23 They are found
in approximately 50% and 20% of East Asian and Caucasian
lung adenocarcinomas, respectively.22,24–26 By contrast,
KRAS mutations are found in 20 to 30% of Caucasian lung
adenocarcinomas but in only 5% of East Asian patients.19,21,27
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KRAS encodes for a GTPase downstream of EGFR. KRAS
mutations are mutually exclusive with EGFR mutations and
are more commonly found in former or current smokers.
The importance of LKB1 mutations remains unclear in
lung adenocarcinomas from Chinese patients. Herein, we
examined the status of LKB1 and clinicopathologic charac-
teristics in a large cohort of Chinese lung adenocarcinomas.
PATIENTS AND METHODS
Chinese Lung Tumor Specimen Collection and
Analyses
The study was approved by the local ethics committees
in Shanghai Cancer Hospital, Fudan University, Shanghai,
China. All 239 lung adenocarcinomas were collected consec-
utively from October 2007 to July 2009, with written in-
formed consents from all patients. Lung tumors were dis-
sected into 3 to 4 small pieces with a diameter of
approximately 3 mm. Each piece was split into two halves;
one half was snap frozen for subsequent genomic analysis,
whereas the other half was processed for histopathological
analysis. Five micrometer-thick hematoxylin and eosin-
stained slides were examined in detail for tumor content. In
each section, we manually counted the number of nuclei to
calculate the percentage of tumor cells, fibroblasts, and in-
flammatory cells. All sections were examined under Nikon
Eclipse 80i microscope with Nikon digital camera
DXM1200C. The picture acquisition software is NIS-Ele-
ments F purchased from Nikon. For one sample, we per-
formed laser capture microdissection with Veritas Laser Cap-
ture Microdissection system (Molecular Devices, Sunnyvale,
CA) using hematoxylin and eosin-stained slides to obtain
tumors cells for further LKB1 mutation analysis.
DNA and RNA Preparation
Genomic DNA or RNA was extracted from snap-frozen
lung tumors or histologically normal lung from distant area as
per standard protocols (RNeasy Mini Kit and QiAamp DNA
Mini Kit; Qiagen, Hilden, Germany). Genomic DNA from
microdissected tumor sample was extracted using QIAamp
DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) following
the manual. Total RNA samples were reverse transcribed into
single-stranded cDNA using RevertAid First Strand cDNA
Synthesis Kit (Fermentas, Vilnius, Lithuania). Either
genomic DNA or cDNAs were used for polymerase chain
reaction (PCR) amplification and sequencing.
PCR Condition and Sequencing Analyses
LKB1 mutation detection was performed on genomic
DNA by PCR amplification and sequencing. The PCR was
done with 5% dimethyl sulfoxide. All LKB1 exons (exon
1–9) were amplified using regular Taq polymerase except for
exon 3 that has very high GC content and was amplified using
KOD-FX (Toyobo, Osaka, Japan). The PCR program (all
exons except for exon 3) was 94°C 3 minutes; 94°C 30
seconds, 58°C 30 seconds (for exons 2, 6, 7, and 8)/45
seconds (for exons 1, 4–5, and 9), 72°C 30 seconds, 35
cycles; 72°C 10 minutes. The program for LKB1 exon 3 was
94°C 2 minutes; 98°C 10 seconds, 68°C 30 seconds, 35
cycles; 68°C 10 minutes. LKB1 PCR and sequencing primer
information is listed in Supplemental Table 1, Supplemental
Digital Content 1, http://links.lww.com/JTO/A32. All sam-
ples with LKB1 mutation were confirmed by resequencing
using genomic DNA.
The EGFR kinase domain mutations were analyzed
using cDNA by PCR amplification and sequencing of the
region spanning exons 18 to 22. The PCR program was 94°C
3 minutes; 94°C 30 seconds, 60°C 30 seconds, 68°C 1 minute
30 seconds, 35 cycles; 68°C 10 minutes. The PCR program
for genomic DNA was 94°C 3 minutes; 94°C 30 seconds,
58°C 30 seconds, 72°C 30 seconds, 35 cycles; 72°C 10
minutes.
The KRAS cDNA region spanning exons 2 to 3 were
amplified using the following program: 94°C 3 minutes; 94°C
30 seconds, 58°C 30 seconds, 72°C 45 seconds, 35 cycles;
72°C 10 minutes. KRAS exon 2 was amplified from genomic
DNA with a program as follows: 94°C 3 minutes; 94°C 30
seconds, 58°C 30 seconds, 72°C 30 seconds, 35 cycles; 72°C
10 minutes.
As for KRAS and EGFR mutation analyses, KOD-plus
(Toyobo, Osaka, Japan) was used for PCR amplification from
cDNA, whereas Taq polymerase was used for PCR amplifi-
cation from genomic DNA. The PCR and sequencing primers
for EGFR and KRAS are listed in Supplemental Table 2, Sup-
plemental Digital Content 1, http://links.lww.com/JTO/A32. All
the EGFR and KRAS mutations found from initial sequencing
analyses of cDNA were confirmed by sequencing of corre-
sponding genomic DNA.
Statistical Analyses
For comparisons of proportions, the Fisher’s exact test
was used. The two-sided significance level was set at
p 0.05. All statistical analyses were performed by using the
R statistical environment (www.r-project.org).
RESULTS
Histopathological Analyses of Chinese Lung
Adenocarcinomas
We collected 239 lung adenocarcinomas consecutively
from October 2007 to July 2009 on institutional review
board-approved protocols. To perform genomic analysis, we
enriched for samples with high tumor content. A high degree
of heterogeneity was observed in the different pieces of all
the 239 samples. Only 33.5% of samples consistently showed
tumor content either lower than 30% (19 samples) or higher
than 70% (61 samples) in all pieces, whereas the remaining
66.6% (159 of 239) showed variability in tumor content (data
not shown). To exclude those tumor samples with low tumor
content, we selected only the tumor samples with at least two
pieces containing 70% tumor cells (Supplemental Table 3,
Supplemental Digital Content 1, http://links.lww.com/JTO/A32).
Thus, 86 patients were examined further for genomic analyses.
LKB1 Mutational Status in Chinese Lung
Adenocarcinoma Samples
Six patients carried somatic LKB1 mutations in Chinese
lung adenocarcinomas (6.9%), consistent with previous re-
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ports on East Asian populations (Table 1). All six specimens
with LKB1 mutations were from men and smokers. There was
no significant association between LKB1 mutation status and
tumor differentiation or clinical stages (Table 1). One tumor
harbored missense mutation (P179L), one had a homozygous
deletion (del50L_53D), which was confirmed by tumor sam-
ple obtained through laser capture microdissection (Figure 1,
Supplemental Figure 1, Supplemental Digital Content 1,
http://links.lww.com/JTO/A32), and one had a nonsense
mutation (Q220stop) (Table 2). The remaining tumors
had intronic splicing-related mutations IVS41 GT,
IVS51 GT, and IVS51 GT, among which the latter
two have been previously reported.21,28 All the mutations
found in six patients were of somatic origin (Figure 1 and
FIGURE 1. Sequencing analysis of tumor sample from laser capture microdissection revealed a homozygous somatic muta-
tion of LKB1. Sequencing results show that the laser capture dissected tumor sample harbored one homozygous LKB1 deletion
mutation del50L_53D (upper part) in contrast to the wild-type LKB1 from histologically normal lung from distant area (lower
part). The 12-bp deletion is illustrated in the sequencing result of normal lung sample.
TABLE 1. LKB1 and EGFR Mutation Profile in Chinese Lung Adenocarcinomas
Variable Total
LKB1 Mutations EGFR Mutations
Positive,
n (%)
Negative,
n (%) pa
Positive,
n (%)
Negative,
n (%) pa
n 86 6 (6.9) 80 (93.1) 57 (66.3) 29 (33.7)
Age (yr)
60 47 6 (12.8) 41 (87.2) 0.03 32 (68.1) 15 (31.9) 0.82
60 39 0 (0) 39 (100) 25 (64.1) 14 (35.9)
Sex
M 49 6 (12.2) 43 (87.8) 0.03 26 (53.1) 23 (46.9) 0
F 37 0 (0) 37 (100) 31 (83.8) 6 (16.2)
Smoking history
Never smokerb 46 0 (0) 46 (100) 0.01 37 (80.4) 9 (19.6) 0.01
Smoker 40 6 (15) 34 (85) 20 (50) 20 (50)
Differentiation
Well to moderate 57 5 (8.8) 52 (91.2) 0.4 42 (73.7) 15 (26.3) 0.06
Poor 29 1 (3.4) 28 (96.6) 15 (51.7) 14 (48.3)
Stage
I–II 47 3 (6.4) 44 (93.6) 1 32 (68.1) 15 (31.9) 0.82
III–IV 39 3 (7.7) 36 (92.3) 25 (64.1) 14 (35.9)
a Fisher’s exact test.
b Never smoker: less than 100 cigarettes in life time.
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Supplemental Figure 2, Supplemental Digital Content 1,
http://links.lww.com/JTO/A32).
Analysis of matched normal lung tissues from distant
area revealed that nine patients harbored a germline F354L
single-nucleotide polymorphism (data not shown). Two of
these patients showed either minimal or no signal for the
wild-type LKB1 allele in their lung cancer samples, suggest-
ing that the tumors may have undergone loss of heterozygos-
ity (Figure 2). The minimal signal is likely due to contami-
nation from stromal cells.
EGFR and KRAS Mutational Status in Chinese
Lung Adenocarcinomas
A total of 57 of 86 lung adenocarcinomas (66.3%)
harbored EGFR kinase domain mutations (Tables 1 and 3).
The majority of EGFR mutations were insertion/deletion
(54.4%) mutations and the L858R (42.1%) point mutation
(Table 3). Among these 57 patients, 26 (45.6%) were males
and 31 (54.4%) were females. Consistent with previous
findings, EGFR mutations were more common in females (31
of 37, 83.8%) than males (26 of 49, 53.1%; p  0.003) and
were significantly correlated with nonsmoking status (80.4%
versus 50%, p 0.006). No significant associations of EGFR
mutations with differentiation status or tumor stage were
observed (Table 1).
By contrast, very few KRAS mutations (2 of 86, 2.3%)
were found in lung adenocarcinomas, which is consistent
with previous studies. The low numbers precluded making
significant clinicopathologic associations. EGFR mutations
and KRAS mutations were mutually exclusive (Table 2).
Correlation Between LKB1 Mutations and EGFR
or KRAS Mutations
One somatic LKB1 somatic mutations occurred simul-
taneously with an EGFR kinase domain mutation, which was
a homozygous del50L_53D mutation (Table 2). In the nine
patients who carried the germline F354L polymorphism, five
also harbored EGFR-mutant tumors (data not shown). Two
LKB1 mutations occurred simultaneously with KRAS muta-
tions (Table 2).
DISCUSSION
Lung adenocarcinomas from Caucasian and East Asian
patients, including Japanese and Korean populations, have
FIGURE 2. Homozygous alteration of LKB1 F354L in two Chinese lung adenocarcinoma patients. Sequencing data showed
that in patients 316 (A) and 370 (B), who carry a germline LKB1 F354L allele (red arrows), this allele was homozygous in their
lung cancer samples. The weak signal of wild-type LKB1 in the lung tumor from patient 370 is likely due to the contaminating
stromal cells.
TABLE 2. Clinicopathologic and Genetic Profiles of Patients with Somatic LKB1 Mutations
Patient
ID Age (yr) Gender
Smoking
Status
Clinical
Stages LKB1 Mutations EGFR Mutations
KRAS
Mutations
180 45.3 M Smoker Ib IVS41GT No No
368 55.2 M Smoker IIIa 536CT (P179L) No 38GA (G13D)
370 42.7 M Smoker IIIa 658CT (Q220stop) No 34GT (G12C)
397 57.2 M Smoker IIb 148_159del12
(del50L_53D)a
2239_2253del15
(del746E_750A)
No
456 44.6 M Smoker Ib IVS51GT No No
481 54.5 M Smoker IIIa IVS51GT No No
a Homozygous deletion.
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been studied extensively for LKB1 mutations, but knowledge
about the status of this gene in Chinese lung adenocarcinomas
is still scant. Herein, we report on the spectrum of LKB1
mutations and their relationship with EGFR and KRAS mu-
tations in a large series of highly annotated lung adenocarci-
nomas from Chinese patients.
Previous studies have indicated that LKB1 mutations
occur frequently in Caucasian lung cancer patients. By con-
trast, the LKB1 mutational rate is relatively lower in either
Japanese or Korean non-small cell lung cancer samples
(approximately 7– 8% of lung adenocarcinomas).21,29,30
Consistent with these results, we found that 6.9% of
Chinese lung adenocarcinomas carried somatic LKB1 mu-
tations (6 of 86).19,30
We found a germline F354L polymorphism in 10.5% (9
of 86) of lung adenocarcinoma patients. The LKB1 F354L
change was originally identified in a sporadic colon cancer
sample but has no impact on LKB1 kinase activity.31,32 This
change was also found in cancer-free individuals from Ko-
rea.31 Thus, the LKB1 F354L allele has been considered as a
nonfunctional polymorphism in previous studies on LKB1
mutations in lung cancer.28,31,33 However, other studies have
identified the LKB1 F354L change in families with Peutz-
Jeghers syndrome.34,35 In contrast to wild-type LKB1, the
F354L allele was found to affect cell polarity maintenance
through dysregulation of the AMPK pathway.35 Recently,
another study has shown that the F354L change was exclu-
sively observed in squamous cell lung carcinoma and large
cell lung carcinoma samples but not in normal lung tissues
from distant area.36 In our study, two patients displayed loss
of heterozygosity of the F354L LKB1 allele in their lung
adenocarcinomas. Nonetheless, only two patients with the
germline F354L polymorphism had family member(s) in-
flicted by digestive system-related cancers and brain cancer.
Our study has no direct evidence to support a role of this
LKB1-mutant allele in tumorigenesis. Further study is war-
ranted to clarify this issue.
LKB1 and EGFR mutations have previously been found
to be mutually exclusive.19,28 Interestingly, one Chinese lung
adenocarcinoma patient carried concurrent somatic mutations
of LKB1 and EGFR in our study. Whether this observation is
a rare event or a phenomenon specifically observed in Chi-
nese lung cancer patients remains to be determined.
Our current analyses of LKB1 mutations mainly relied
on DNA sequencing and thus may underestimate the real
percentage of LKB1 loss-of-function status in lung cancer.
Our previous study identified large fragment loss of the LKB1
allele using Multiplex Ligation-dependent Probe Amplifica-
tion,20 which is more sensitive than direct sequencing at
detecting LKB1 changes. In addition, although methylation of
the LKB1 promoter region in lung cancer has not yet been
reported, it is possible that epigenetic regulation of LKB1
expression exists in human lung cancer. Further detailed
analyses are warranted to find the real percentage of LKB1
functional loss in Chinese lung adenocarcinomas.
In summary, we have analyzed the status of LKB1
mutations, in conjunction with EGFR and KRAS mutations, in
lung adenocarcinomas from Chinese patients using patholog-
ically well-annotated clinical samples. These data provide a
picture of the genetic landscape found in Chinese lung ade-
nocarcinomas and offer a framework from which to develop
specific targeted therapies in this patient population.
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